יחס שווי שוק לשווי בספרים: pharvaris.com (PHVS)

The primary driver for Pharvaris N.V. (PHVS) is the development of an innovative tablet-based treatment for hereditary angioedema, as confirmed by the price action chart, where the indicator is fixed at 6.74. The biotech firm focuses on orphan disease therapies, implementing energy-efficient technologies and a closed-loop water cycle. Business success relies on regulatory approvals and prudent cost management supported by stable investment capital.

This ratio is calculated as the ratio of the total market value of all shares to the sum of net assets, reflecting the premium or discount of the market price relative to real capital. For Pharvaris N.V. (PHVS), which utilizes outsourced manufacturing, the current market capitalization valuation relative to book value on GURU.Markets demonstrates the value of intellectual capital and future developments that are not reflected in the company's physical asset value.